Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Aug 15;100(4):855–866. doi: 10.1172/JCI119601

Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.

E J Claret 1, E P Alyea 1, E Orsini 1, C C Pickett 1, H Collins 1, Y Wang 1, D Neuberg 1, R J Soiffer 1, J Ritz 1
PMCID: PMC508258  PMID: 9259585

Abstract

The clinical efficacy of donor lymphocyte infusions (DLI) in patients with relapsed chronic myelocytic leukemia after allogeneic bone marrow transplantation has been demonstrated in several recent studies. Although it is presumed that allogeneic T cells mediate this graft-versus-leukemia (GVL) effect, the influence of DLI on the T cell compartment of recipients has not been determined. To characterize the immunologic effects of DLI and to identify T cell changes selectively associated with the GVL response, we analyzed the T cell receptor (TCR) repertoire in four patients with relapsed chronic myelocytic leukemia who achieved a complete remission after infusion of CD4+ lymphocytes from HLA-identical sibling donors. Only one of the four patients developed clinically significant graft-versus-host disease (GVHD) after infusion of donor lymphocytes. TCR repertoire was examined after PCR amplification of 24 Vbeta gene subfamilies in serial samples obtained over a 1-yr period before and after DLI. Results were compared to 10 normal donors. Before DLI, all four patients were found to have abnormal TCR Vbeta repertoire in peripheral T cells, associated with a large number of clonal and oligoclonal patterns. Abnormal TCR patterns persisted for at least 3 mo after DLI, but thereafter gradually began to normalize. By 1 yr after DLI, all patients demonstrated almost complete normalization of Vbeta repertoire with polyclonal representation within almost all Vbeta gene subfamilies. We also examined changes in the TCR Vbeta repertoire associated with the disappearance of Ph+ cells. In each patient, we were able to identify the expansion of at least 1 Vbeta gene subfamily that coincided with the time of the cytogenetic response. In one patient who was studied in greater detail, CDR3 size analysis of serial samples after DLI indicated that these changes were associated with the appearance of clonal T cells. This finding was confirmed through CDR3 sequence analysis and use of CDR3 clone-specific oligonucleotide probes. A putative GVL clone identified by this technique was not detectable in either donor or patient T cells before DLI, but persisted in peripheral T cells for approximately 1 yr. These experiments therefore provide evidence for the clonal expansion of allogeneic T cells that may be selective mediators of antileukemia activity without also mediating graft-versus-host disease.

Full Text

The Full Text of this article is available as a PDF (333.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akatsuka Y., Cerveny C., Hansen J. A. T cell receptor clonal diversity following allogeneic marrow grafting. Hum Immunol. 1996 Jun-Jul;48(1-2):125–134. doi: 10.1016/0198-8859(96)00082-1. [DOI] [PubMed] [Google Scholar]
  2. Akolkar P. N., Gulwani-Akolkar B., Pergolizzi R., Bigler R. D., Silver J. Influence of HLA genes on T cell receptor V segment frequencies and expression levels in peripheral blood lymphocytes. J Immunol. 1993 Apr 1;150(7):2761–2773. [PubMed] [Google Scholar]
  3. Antin J. H. Graft-versus-leukemia: no longer an epiphenomenon. Blood. 1993 Oct 15;82(8):2273–2277. [PubMed] [Google Scholar]
  4. Callan M. F., Steven N., Krausa P., Wilson J. D., Moss P. A., Gillespie G. M., Bell J. I., Rickinson A. B., McMichael A. J. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med. 1996 Aug;2(8):906–911. doi: 10.1038/nm0896-906. [DOI] [PubMed] [Google Scholar]
  5. Choi Y. W., Kotzin B., Herron L., Callahan J., Marrack P., Kappler J. Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc Natl Acad Sci U S A. 1989 Nov;86(22):8941–8945. doi: 10.1073/pnas.86.22.8941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Collins R. H., Jr, Shpilberg O., Drobyski W. R., Porter D. L., Giralt S., Champlin R., Goodman S. A., Wolff S. N., Hu W., Verfaillie C. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997 Feb;15(2):433–444. doi: 10.1200/JCO.1997.15.2.433. [DOI] [PubMed] [Google Scholar]
  7. DeBruyne L. A., Lynch J. P., 3rd, Baker L. A., Florn R., Deeb G. M., Whyte R. I., Bishop D. K. Restricted V beta usage by T cells infiltrating rejecting human lung allografts. J Immunol. 1996 May 1;156(9):3493–3500. [PubMed] [Google Scholar]
  8. Delage R., Soiffer R. J., Dear K., Ritz J. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood. 1991 Nov 15;78(10):2759–2767. [PubMed] [Google Scholar]
  9. Dietrich P. Y., Caignard A., Diu A., Genevee C., Pico J. L., Henry-Amar M., Bosq J., Angevin E., Triebel F., Hercend T. Analysis of T-cell receptor variability in transplanted patients with acute graft-versus-host disease. Blood. 1992 Nov 1;80(9):2419–2424. [PubMed] [Google Scholar]
  10. Dietrich P. Y., Caignard A., Lim A., Chung V., Pico J. L., Pannetier C., Kourilsky P., Hercend T., Even J., Triebel F. In vivo T-cell clonal amplification at time of acute graft-versus-host disease. Blood. 1994 Oct 15;84(8):2815–2820. [PubMed] [Google Scholar]
  11. Faber L. M., van Luxemburg-Heijs S. A., Veenhof W. F., Willemze R., Falkenburg J. H. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood. 1995 Oct 1;86(7):2821–2828. [PubMed] [Google Scholar]
  12. Gaschet J., Lim A., Liem L., Vivien R., Hallet M. M., Harousseau J. L., Even J., Goulmy E., Bonneville M., Milpied N. Acute graft versus host disease due to T lymphocytes recognizing a single HLA-DPB1*0501 mismatch. J Clin Invest. 1996 Jul 1;98(1):100–107. doi: 10.1172/JCI118753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gaschet J., Treviño M. A., Cherel M., Vivien R., Garcia-Sahuquillo A., Hallet M. M., Bonneville M., Harrousseau J. L., Bragado R., Milpied N. HLA-target antigens and T-cell receptor diversity of activated T cells invading the skin during acute graft-versus-host disease. Blood. 1996 Mar 15;87(6):2345–2353. [PubMed] [Google Scholar]
  14. Genevée C., Diu A., Nierat J., Caignard A., Dietrich P. Y., Ferradini L., Roman-Roman S., Triebel F., Hercend T. An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur J Immunol. 1992 May;22(5):1261–1269. doi: 10.1002/eji.1830220522. [DOI] [PubMed] [Google Scholar]
  15. Giralt S. A., Champlin R. E. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood. 1994 Dec 1;84(11):3603–3612. [PubMed] [Google Scholar]
  16. Giralt S., Hester J., Huh Y., Hirsch-Ginsberg C., Rondón G., Seong D., Lee M., Gajewski J., Van Besien K., Khouri I. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995 Dec 1;86(11):4337–4343. [PubMed] [Google Scholar]
  17. Goldman J. M., Gale R. P., Horowitz M. M., Biggs J. C., Champlin R. E., Gluckman E., Hoffmann R. G., Jacobsen S. J., Marmont A. M., McGlave P. B. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988 Jun;108(6):806–814. doi: 10.7326/0003-4819-108-6-806. [DOI] [PubMed] [Google Scholar]
  18. Gorochov G., Debré P., Leblond V., Sadat-Sowti B., Sigaux F., Autran B. Oligoclonal expansion of CD8+ CD57+ T cells with restricted T-cell receptor beta chain variability after bone marrow transplantation. Blood. 1994 Jan 15;83(2):587–595. [PubMed] [Google Scholar]
  19. Gorski J., Yassai M., Zhu X., Kissela B., Kissella B [corrected to Kissela B. ]., Keever C., Flomenberg N. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J Immunol. 1994 May 15;152(10):5109–5119. [PubMed] [Google Scholar]
  20. Goulmy E., Schipper R., Pool J., Blokland E., Falkenburg J. H., Vossen J., Gratwohl A., Vogelsang G. B., van Houwelingen H. C., van Rood J. J. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996 Feb 1;334(5):281–285. doi: 10.1056/NEJM199602013340501. [DOI] [PubMed] [Google Scholar]
  21. Hingorani R., Choi I. H., Akolkar P., Gulwani-Akolkar B., Pergolizzi R., Silver J., Gregersen P. K. Clonal predominance of T cell receptors within the CD8+ CD45RO+ subset in normal human subjects. J Immunol. 1993 Nov 15;151(10):5762–5769. [PubMed] [Google Scholar]
  22. Horowitz M. M., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H. J., Rimm A. A., Ringdén O., Rozman C., Speck B. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990 Feb 1;75(3):555–562. [PubMed] [Google Scholar]
  23. Kolb H. J., Mittermüller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990 Dec 15;76(12):2462–2465. [PubMed] [Google Scholar]
  24. Kolb H. J., Schattenberg A., Goldman J. M., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A., Verdonck L., Niederwieser D. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995 Sep 1;86(5):2041–2050. [PubMed] [Google Scholar]
  25. Kubo K., Yamanaka K., Kiyoi H., Fukutani H., Ito M., Hayakawa R., Ohno R., Naoe T. Different T-cell receptor repertoires between lesions and peripheral blood in acute graft-versus-host disease after allogeneic bone marrow transplantation. Blood. 1996 Apr 1;87(7):3019–3026. [PubMed] [Google Scholar]
  26. Liu X., Chesnokova V., Forman S. J., Diamond D. J. Molecular analysis of T-cell receptor repertoire in bone marrow transplant recipients: evidence for oligoclonal T-cell expansion in graft-versus-host disease lesions. Blood. 1996 Apr 1;87(7):3032–3044. [PubMed] [Google Scholar]
  27. Mackinnon S., Papadopoulos E. B., Carabasi M. H., Reich L., Collins N. H., Boulad F., Castro-Malaspina H., Childs B. H., Gillio A. P., Kernan N. A. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995 Aug 15;86(4):1261–1268. [PubMed] [Google Scholar]
  28. Marmont A. M., Horowitz M. M., Gale R. P., Sobocinski K., Ash R. C., van Bekkum D. W., Champlin R. E., Dicke K. A., Goldman J. M., Good R. A. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991 Oct 15;78(8):2120–2130. [PubMed] [Google Scholar]
  29. Marmont A. M. The graft versus leukemia (GVL) effect after allogeneic bone marrow transplantation for chronic myelogenous leukemia (CML). Leuk Lymphoma. 1993;11 (Suppl 1):221–226. doi: 10.3109/10428199309047890. [DOI] [PubMed] [Google Scholar]
  30. Masuko K., Kato S., Hagihara M., Tsuchida F., Takemoto Y., Izawa K., Kato T., Yamamori S., Mizushima Y., Nishioka K. Stable clonal expansion of T cells induced by bone marrow transplantation. Blood. 1996 Jan 15;87(2):789–799. [PubMed] [Google Scholar]
  31. Mehta J. Graft-versus-leukemia reactions in clinical bone marrow transplantation. Leuk Lymphoma. 1993 Aug;10(6):427–432. doi: 10.3109/10428199309148199. [DOI] [PubMed] [Google Scholar]
  32. Pannetier C., Cochet M., Darche S., Casrouge A., Zöller M., Kourilsky P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci U S A. 1993 May 1;90(9):4319–4323. doi: 10.1073/pnas.90.9.4319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Pichert G., Roy D. C., Gonin R., Alyea E. P., Bélanger R., Gyger M., Perreault C., Bonny Y., Lerra I., Murray C. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol. 1995 Jul;13(7):1704–1713. doi: 10.1200/JCO.1995.13.7.1704. [DOI] [PubMed] [Google Scholar]
  34. Porter D. L., Roth M. S., McGarigle C., Ferrara J. L., Antin J. H. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994 Jan 13;330(2):100–106. doi: 10.1056/NEJM199401133300204. [DOI] [PubMed] [Google Scholar]
  35. Puisieux I., Even J., Pannetier C., Jotereau F., Favrot M., Kourilsky P. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol. 1994 Sep 15;153(6):2807–2818. [PubMed] [Google Scholar]
  36. Roux E., Helg C., Chapuis B., Jeannet M., Roosnek E. T-cell repertoire complexity after allogeneic bone marrow transplantation. Hum Immunol. 1996 Jun-Jul;48(1-2):135–138. doi: 10.1016/0198-8859(96)00085-7. [DOI] [PubMed] [Google Scholar]
  37. Roux E., Helg C., Dumont-Girard F., Chapuis B., Jeannet M., Roosnek E. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood. 1996 May 1;87(9):3984–3992. [PubMed] [Google Scholar]
  38. Rowen L., Koop B. F., Hood L. The complete 685-kilobase DNA sequence of the human beta T cell receptor locus. Science. 1996 Jun 21;272(5269):1755–1762. doi: 10.1126/science.272.5269.1755. [DOI] [PubMed] [Google Scholar]
  39. Slavin S., Naparstek E., Nagler A., Ackerstein A., Samuel S., Kapelushnik J., Brautbar C., Or R. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 1996 Mar 15;87(6):2195–2204. [PubMed] [Google Scholar]
  40. Soiffer R. J., Murray C., Mauch P., Anderson K. C., Freedman A. S., Rabinowe S. N., Takvorian T., Robertson M. J., Spector N., Gonin R. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol. 1992 Jul;10(7):1191–1200. doi: 10.1200/JCO.1992.10.7.1191. [DOI] [PubMed] [Google Scholar]
  41. Weiden P. L., Flournoy N., Thomas E. D., Prentice R., Fefer A., Buckner C. D., Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979 May 10;300(19):1068–1073. doi: 10.1056/NEJM197905103001902. [DOI] [PubMed] [Google Scholar]
  42. Weiden P. L., Sullivan K. M., Flournoy N., Storb R., Thomas E. D. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981 Jun 18;304(25):1529–1533. doi: 10.1056/NEJM198106183042507. [DOI] [PubMed] [Google Scholar]
  43. Weisdorf D. J., Nesbit M. E., Ramsay N. K., Woods W. G., Goldman A. I., Kim T. H., Hurd D. D., McGlave P. B., Kersey J. H. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease. J Clin Oncol. 1987 Sep;5(9):1348–1355. doi: 10.1200/JCO.1987.5.9.1348. [DOI] [PubMed] [Google Scholar]
  44. Yamanaka K., Kwok W. W., Mickelson E. M., Masewicz S., Smith F., Nepom G. T. Selective T-cell-receptor gene usage in allorecognition and graft-versus-host disease. Transplantation. 1993 May;55(5):1167–1175. doi: 10.1097/00007890-199305000-00043. [DOI] [PubMed] [Google Scholar]
  45. thor Straten P., Becker J. C., Seremet T., Bröcker E. B., Zeuthen J. Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J Clin Invest. 1996 Jul 15;98(2):279–284. doi: 10.1172/JCI118790. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES